First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors.
Bédard PL, Davies MA, Kopetz S, Juric D, Shapiro GI, Luke JJ, Spreafico A, Wu B, Castell C, Gomez C, Cartot-Cotton S, Mazuir F, Dubar M, Micallef S, Demers B, Flaherty KT.
Bédard PL, et al. Among authors: cartot cotton s.
Cancer. 2018 Jan 15;124(2):315-324. doi: 10.1002/cncr.31044. Epub 2017 Oct 4.
Cancer. 2018.
PMID: 28976556
Free article.